These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 1391232)

  • 1. Systemic administration of recombinant interleukin-6 in mice induces proliferation of lymphoid cells in vivo.
    Puri RK; Leland P
    Lymphokine Cytokine Res; 1992 Jun; 11(3):133-9. PubMed ID: 1391232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
    Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
    J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo administration of interferon alpha and interleukin 2 induces proliferation of lymphoid cells in the organs of mice.
    Puri RK; Travis WD; Rosenberg SA
    Cancer Res; 1990 Sep; 50(17):5543-50. PubMed ID: 2386960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
    Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.
    Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
    J Immunol; 1985 Aug; 135(2):1488-97. PubMed ID: 3891854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of murine lymphokine-activated killer cells by recombinant IL-7.
    Lynch DH; Miller RE
    J Immunol; 1990 Sep; 145(6):1983-90. PubMed ID: 1975262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE; Rosenberg SA
    Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
    Mulé JJ; Yang J; Shu S; Rosenberg SA
    J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphokine-activated killer cells in rats: analysis of tissue and strain distribution, ontogeny, and target specificity.
    Vujanovic NL; Herberman RB; Hiserodt JC
    Cancer Res; 1988 Feb; 48(4):878-83. PubMed ID: 3257411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.
    Butler LD; Browne CP; Layman NK; Riedl P; Tang J; Marder P; DeLong D; Manetta J; Bobbitt L; Strnad J
    Cancer Res; 1988 Nov; 48(21):6081-9. PubMed ID: 3048654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The in vitro antitumor effectiveness of murine lymphokine-activated killer (LAK) cells induced by recombinant IL-2].
    Okamoto Y; Shimizu K; Miyao Y; Ushio Y; Matsui Y; Hayakawa T; Tsuda N; Mogami H
    No To Shinkei; 1986 Mar; 38(3):233-7. PubMed ID: 3486667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H; Vitolo D; Altarac S; Herberman RB; Whiteside TL
    J Immunol; 1992 Jul; 149(1):340-9. PubMed ID: 1535088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity and immunologic effects of continuous infusion of recombinant human interleukin-2 administered by selective hepatic perfusion in dogs.
    Da Pozzo LF; Hough KL; Holder WD
    Surgery; 1992 Mar; 111(3):326-34. PubMed ID: 1542858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine).
    Pope BL; Chourmouzis E; Sigindere J; MacIntyre JP; Capetola RJ; Lau CY
    Cell Immunol; 1993 Apr; 147(2):302-12. PubMed ID: 8453674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-4-induced lymphokine-activated killer cells. Lytic activity is mediated by phenotypically distinct natural killer-like and T cell-like large granular lymphocytes.
    Peace DJ; Kern DE; Schultz KR; Greenberg PD; Cheever MA
    J Immunol; 1988 May; 140(10):3679-85. PubMed ID: 2896213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction and persistence in vivo of NK/LAK activity by a mannoprotein component of Candida albicans cell wall.
    Scaringi L; Cornacchione P; Rosati E; Fettucciari K; Rossi R; Marconi P
    Cell Immunol; 1994 May; 155(2):265-82. PubMed ID: 8181065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.